13,14-dihydro-15-keto-tetranor Prostaglandin E2
- $98 - $437
- Product name: 13,14-dihydro-15-keto-tetranor Prostaglandin E2
- CAS: 20675-85-8
- MF: C16H26O5
- MW: 298.37
- EINECS:
- MDL Number:MFCD18428006
- Synonyms:13,14-dihydro-15-keto-tetranor Prostaglandin E2;13,14-dihydro-15-keto-tetranor Prostaglandin E2 Exclusive;Cyclopentanepropanoic acid, 3-hydroxy-5-oxo-2-(3-oxooctyl)-, [1R-(1α,2β,3α)]- (9CI)
3 prices
Selected condition:
Brand
- Cayman Chemical
Package
- 10μg
- 25μg
- 50μg
- ManufacturerCayman Chemical
- Product number13101
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95%
- Packaging10μg
- Price$98
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number13101
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95%
- Packaging25μg
- Price$232
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number13101
- Product description13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95%
- Packaging50μg
- Price$437
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 10μg | $98 | 2024-03-01 | Buy |
Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 25μg | $232 | 2024-03-01 | Buy |
Cayman Chemical | 13101 | 13,14-dihydro-15-keto-tetranor Prostaglandin E2 ≥95% | 50μg | $437 | 2024-03-01 | Buy |
Properties
Boiling point :497.7±30.0 °C(Predicted)
Density :1.127±0.06 g/cm3(Predicted)
solubility :DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml
pka :4.61±0.10(Predicted)
Density :1.127±0.06 g/cm3(Predicted)
solubility :DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml
pka :4.61±0.10(Predicted)
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||||
Precautionary statements: |
|